Asimadoline
AssetAlso TP0052, EMD-61753
Activates peripheral kappa-opioid receptors to treat menopausal vasomotor symptoms.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- OPRK1
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Vasomotor symptoms
Phase 2, Recruiting, NCT07042516, clinicaltrials.gov, 11 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Competitors8
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.